Neoadjuvant trastuzumab deruxtecan combination therapy reduces the residual cancer burden in high-risk early breast cancer, ...

The 2026 heme-onc pipeline accelerates with Karyopharm Therapeutics announcing a label expansion for selinexor following a late-stage myelofibrosis win, while the GBM AGILE trial definitively closes ...

Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - ...

TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic ...

Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive ...

MEDSIR, an international company and a leader in oncology research, has presented the results of the PHERGain and PHERGain-2 ...

Broader Vyvgart access: Vyvgart can now be prescribed to all adult gMG serotypes, extending its reach beyond anti-AChR-positive patients. Evorpacept trial success: ALX Oncology reported 100% response ...

Vepdegestrant becomes the first FDA-approved heterobifunctional protein degrader (PROTAC) in breast cancer, targeting ER ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...